Key facts
- The U.K. regulator has licensed a medicine.
- This is the third regulatory authority to grant a license for the drug.
- The Danish drugmaker is seeking to regain its lead in the obesity market.
The U.K. regulator has granted a license for a new medicine, making it the third regulatory authority worldwide to approve the drug. This development is part of the Danish drugmaker's strategy to re-establish its dominance in the highly competitive obesity market.